1whl: Difference between revisions

No edit summary
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:


==Solution structure of the 1st CAP-Gly domain in human cylindromatosis tumor suppressor CYLD==
==Solution structure of the 1st CAP-Gly domain in human cylindromatosis tumor suppressor CYLD==
<StructureSection load='1whl' size='340' side='right'caption='[[1whl]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''>
<StructureSection load='1whl' size='340' side='right'caption='[[1whl]]' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[1whl]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1WHL OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=1WHL FirstGlance]. <br>
<table><tr><td colspan='2'>[[1whl]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1WHL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1WHL FirstGlance]. <br>
</td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Kazusa cDNA fh04363 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=1whl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1whl OCA], [http://pdbe.org/1whl PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1whl RCSB], [http://www.ebi.ac.uk/pdbsum/1whl PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=1whl ProSAT], [http://www.topsan.org/Proteins/RSGI/1whl TOPSAN]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1whl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1whl OCA], [https://pdbe.org/1whl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1whl RCSB], [https://www.ebi.ac.uk/pdbsum/1whl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1whl ProSAT], [https://www.topsan.org/Proteins/RSGI/1whl TOPSAN]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
[[http://www.uniprot.org/uniprot/CYLD_HUMAN CYLD_HUMAN]] Defects in CYLD are the cause of familial cylindromatosis (FCYL) [MIM:[http://omim.org/entry/132700 132700]]; also known as Ancell-Spiegler cylindromas or turban tumor syndrome or dermal eccrine cylindromatosis. CYLD is an autosomal dominant and highly tumor type-specific disorder. The tumors (known as cylindromas because of their characteristic microscopic architecture) are believed to arise from or recapitulate the appearance of the eccrine or apocrine cells of the skin that secrete sweat and scent respectively. Cylindromas arise predominantly in hairy parts of the body with approximately 90% on the head and neck. The development of a confluent mass which may ulcerate or become infected has led to the designation 'turban tumor syndrome'. The skin tumors show differentiation in the direction of hair structures, hence the synonym trichoepithelioma.<ref>PMID:12190880</ref> <ref>PMID:16922728</ref>  Defects in CYLD are the cause of multiple familial trichoepithelioma type 1 (MFT1) [MIM:[http://omim.org/entry/601606 601606]]; also known as epithelioma adenoides cysticum of Brooke (EAC) or hereditary multiple benign cystic epithelioma or Brooke-Fordyce trichoepitheliomas. MFT1 is an autosomal dominant dermatosis characterized by the presence of many skin tumors predominantly on the face. Since histologic examination shows dermal aggregates of basaloid cells with connection to or differentiation toward hair follicles, this disorder has been thought to represent a benign hamartoma of the pilosebaceous apparatus. Trichoepitheliomas can degenerate into basal cell carcinoma.<ref>PMID:16922728</ref> <ref>PMID:14632188</ref> <ref>PMID:16307661</ref>  Defects in CYLD are the cause of Brooke-Spiegler syndrome (BRSS) [MIM:[http://omim.org/entry/605041 605041]]. BRSS is an autosomal dominant disorder characterized by the appearance of multiple skin appendage tumors such as cylindroma, trichoepithelioma, and spiradenoma. These tumors are typically located in the head and neck region, appear in early adulthood, and gradually increase in size and number throughout life.<ref>PMID:12190880</ref> <ref>PMID:14632188</ref> <ref>PMID:12950348</ref> <ref>PMID:15854031</ref>
[https://www.uniprot.org/uniprot/CYLD_HUMAN CYLD_HUMAN] Defects in CYLD are the cause of familial cylindromatosis (FCYL) [MIM:[https://omim.org/entry/132700 132700]; also known as Ancell-Spiegler cylindromas or turban tumor syndrome or dermal eccrine cylindromatosis. CYLD is an autosomal dominant and highly tumor type-specific disorder. The tumors (known as cylindromas because of their characteristic microscopic architecture) are believed to arise from or recapitulate the appearance of the eccrine or apocrine cells of the skin that secrete sweat and scent respectively. Cylindromas arise predominantly in hairy parts of the body with approximately 90% on the head and neck. The development of a confluent mass which may ulcerate or become infected has led to the designation 'turban tumor syndrome'. The skin tumors show differentiation in the direction of hair structures, hence the synonym trichoepithelioma.<ref>PMID:12190880</ref> <ref>PMID:16922728</ref>  Defects in CYLD are the cause of multiple familial trichoepithelioma type 1 (MFT1) [MIM:[https://omim.org/entry/601606 601606]; also known as epithelioma adenoides cysticum of Brooke (EAC) or hereditary multiple benign cystic epithelioma or Brooke-Fordyce trichoepitheliomas. MFT1 is an autosomal dominant dermatosis characterized by the presence of many skin tumors predominantly on the face. Since histologic examination shows dermal aggregates of basaloid cells with connection to or differentiation toward hair follicles, this disorder has been thought to represent a benign hamartoma of the pilosebaceous apparatus. Trichoepitheliomas can degenerate into basal cell carcinoma.<ref>PMID:16922728</ref> <ref>PMID:14632188</ref> <ref>PMID:16307661</ref>  Defects in CYLD are the cause of Brooke-Spiegler syndrome (BRSS) [MIM:[https://omim.org/entry/605041 605041]. BRSS is an autosomal dominant disorder characterized by the appearance of multiple skin appendage tumors such as cylindroma, trichoepithelioma, and spiradenoma. These tumors are typically located in the head and neck region, appear in early adulthood, and gradually increase in size and number throughout life.<ref>PMID:12190880</ref> <ref>PMID:14632188</ref> <ref>PMID:12950348</ref> <ref>PMID:15854031</ref>  
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/CYLD_HUMAN CYLD_HUMAN]] Protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity).<ref>PMID:12917689</ref> <ref>PMID:12917690</ref> <ref>PMID:12917691</ref> <ref>PMID:14676304</ref> <ref>PMID:15870263</ref> <ref>PMID:17495026</ref> <ref>PMID:18636086</ref> <ref>PMID:18222923</ref> <ref>PMID:20194890</ref> <ref>PMID:19893491</ref> <ref>PMID:20227366</ref> <ref>PMID:18313383</ref>
[https://www.uniprot.org/uniprot/CYLD_HUMAN CYLD_HUMAN] Protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity).<ref>PMID:12917689</ref> <ref>PMID:12917690</ref> <ref>PMID:12917691</ref> <ref>PMID:14676304</ref> <ref>PMID:15870263</ref> <ref>PMID:17495026</ref> <ref>PMID:18636086</ref> <ref>PMID:18222923</ref> <ref>PMID:20194890</ref> <ref>PMID:19893491</ref> <ref>PMID:20227366</ref> <ref>PMID:18313383</ref>  
== Evolutionary Conservation ==
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
[[Image:Consurf_key_small.gif|200px|right]]
Line 21: Line 21:
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1whl ConSurf].
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1whl ConSurf].
<div style="clear:both"></div>
<div style="clear:both"></div>
==See Also==
*[[CAP-Gly domain|CAP-Gly domain]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Inoue, M]]
[[Category: Inoue M]]
[[Category: Kigawa, T]]
[[Category: Kigawa T]]
[[Category: Koshiba, S]]
[[Category: Koshiba S]]
[[Category: Structural genomic]]
[[Category: Saito K]]
[[Category: Saito, K]]
[[Category: Yokoyama S]]
[[Category: Yokoyama, S]]
[[Category: Antitumor protein]]
[[Category: Deubiquitinating enzyme]]
[[Category: Rsgi]]
[[Category: Tumor suppressor]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA